Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957199 | 0.82 | HTR7 (0.41) | KDM4EALDH1A1GAARAB9ACSNK1D | |
| SCHEMBL2954143 | 0.81 | MAPK14 (0.60) | ALDH1A1GLACSNK1DMAPK14HTR2A | |
| Hydrochloric Acid SCHEMBL2955401 | 0.80 | MAPK14 (0.58) | ALDH1A1CSNK1DMAPK14HTR2AHTR7 | |
| SCHEMBL27786505 | 0.77 | CSNK1D (0.40) | KDM4EALDH1A1HPGDCSNK1DMAPK14 | |
| SCHEMBL2958371 | 0.76 | CKS1B (0.55) | ALDH1A1MET | |
| SCHEMBL2958555 | 0.75 | HPGD (0.40) | KDM4EALDH1A1GLAHPGDCSNK1D | |
| SCHEMBL2957272 | 0.75 | HPGD (0.40) | KDM4EALDH1A1GLAHPGDCSNK1D | |
| SCHEMBL2954842 | 0.74 | HRH3 (0.45) | HPGDRAB9ACSNK1DMAPK14HRH3 | |
| SCHEMBL10633640 | 0.73 | KDM4E (0.55) | KDM4EALDH1A1SMN1; SMN2GAAHPGD | |
| Tert-Butyl Formate SCHEMBL27786506 | 0.73 | MAPK14 (0.48) | KDM4EALDH1A1CSNK1DMAPK14DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422296-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-13 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| US-8791120-B2 | Fast-dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2121630-B1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-01 | — | — | EP | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-03-18 | — | — | US | disclosed |
| EP-2121630-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008098892-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008098892-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336381-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | KDM4E 2363/4885ALDH1A1 1836/4885SMN1; SMN2 979/4885 |
| US-20100069394-A1 | FAST-DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | KDM4E 2363/4885ALDH1A1 1836/4885SMN1; SMN2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.